Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdullah Sakin

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Cancer Investigation|December 5, 2025
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group StudyMukremin Uysal, Sezer Saglam, İsmail Beypınar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2024
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRCMahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, et al.
Journal of Chemotherapy (Florence, Italy)|June 21, 2024
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter studyÖzgecan Dülgar, Sema Türker, Gül Başaran, et al.
Neoplasma|January 9, 2023
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective studyElvina Almuradova, Tugba Basoglu, Erdinc Nayir, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Studyİlknur Deliktaş Onur, Mutlu Doğan, Mehmet Akif Öztürk, et al.
BMC Cancer|February 14, 2026
Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) studyZehra Sucuoğlu İşleyen, Şaban Seçmeler, Abdullah Sakin, et al.
Clinical Genitourinary Cancer|April 16, 2024
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, et al.
Journal of Geriatric Oncology|September 8, 2023
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyOkan Avcı, Yakup İriağaç, Eyyüp Çavdar, et al.
BMC Cancer|January 3, 2024
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerElif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, et al.
BMC Cancer|January 23, 2024
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerElif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Cancer Investigation|December 5, 2025
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group StudyMukremin Uysal, Sezer Saglam, İsmail Beypınar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2024
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRCMahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, et al.
Journal of Chemotherapy (Florence, Italy)|June 21, 2024
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter studyÖzgecan Dülgar, Sema Türker, Gül Başaran, et al.
Neoplasma|January 9, 2023
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective studyElvina Almuradova, Tugba Basoglu, Erdinc Nayir, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Studyİlknur Deliktaş Onur, Mutlu Doğan, Mehmet Akif Öztürk, et al.
BMC Cancer|February 14, 2026
Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) studyZehra Sucuoğlu İşleyen, Şaban Seçmeler, Abdullah Sakin, et al.
Clinical Genitourinary Cancer|April 16, 2024
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, et al.
Journal of Geriatric Oncology|September 8, 2023
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyOkan Avcı, Yakup İriağaç, Eyyüp Çavdar, et al.
BMC Cancer|January 3, 2024
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerElif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, et al.
BMC Cancer|January 23, 2024
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerElif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, et al.
Pageof 11